{"entity":{"type":"insider","cik":"0001612134","url":"/insider/0001612134","json_url":"/insider/0001612134.json","name":"Sofinnova Management IX, L.L.C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":8,"first":"2015-05-14","last":"2020-08-12","span_basis":"filed_date"},"name_variants":[{"name":"Sofinnova Management IX, L.L.C.","source":"filing","n_filings":8,"first_seen":"2015-05-14","last_seen":"2020-08-12"}],"transactions":[{"id":2133200,"accession":"0000899243-20-022200","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-022200","line_url":"/filing/0000899243-20-022200#line-2","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"HEALY JAMES; POWELL MICHAEL; Sofinnova Venture Partners IX, L.P.; Sofinnova Management IX, L.L.C.","owner_display_name":"HEALY JAMES","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":133333.0,"shares_display":"133,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1999995.0,"total_display":"1,999,995.00","total_whole":"1,999,995","shares_owned_after":3606707.0,"shares_owned_after_display":"3,606,707","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-11","filed_date":"2020-08-12","scope":"insider"},{"id":2213005,"accession":"0001104659-20-069570","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-069570","line_url":"/filing/0001104659-20-069570#line-2","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Iterum Therapeutics plc","issuer_ticker":"ITRM","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Management IX, L.L.C.; POWELL MICHAEL; HEALY JAMES; Sofinnova Venture Partners IX, L.P.","owner_display_name":"Sofinnova Management IX, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400000.0,"shares_display":"400,000","price_per_share":1.6074,"price_display":"1.61","price_state":"stated","total_value":642960.0,"total_display":"642,960.00","total_whole":"642,960","shares_owned_after":1226514.0,"shares_owned_after_display":"1,226,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-02","filed_date":"2020-06-03","scope":"insider"},{"id":2213001,"accession":"0001104659-20-069570","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-069570","line_url":"/filing/0001104659-20-069570#line-1","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Iterum Therapeutics plc","issuer_ticker":"ITRM","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Management IX, L.L.C.; POWELL MICHAEL; HEALY JAMES; Sofinnova Venture Partners IX, L.P.","owner_display_name":"Sofinnova Management IX, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":1.6912,"price_display":"1.69","price_state":"stated","total_value":169120.0,"total_display":"169,120.00","total_whole":"169,120","shares_owned_after":1626514.0,"shares_owned_after_display":"1,626,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-01","filed_date":"2020-06-03","scope":"insider"},{"id":8699222,"accession":"0001104659-19-065582","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-065582","line_url":"/filing/0001104659-19-065582#line-1","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"POWELL MICHAEL; Sofinnova Venture Partners IX, L.P.; Sofinnova Management IX, L.L.C.; Mehra Anand; HEALY JAMES","owner_display_name":"POWELL MICHAEL","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":36.75,"price_display":"36.75","price_state":"stated","total_value":5512500.0,"total_display":"5,512,500.00","total_whole":"5,512,500","shares_owned_after":2671856.0,"shares_owned_after_display":"2,671,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-15","filed_date":"2019-11-19","scope":"insider"},{"id":7775857,"accession":"0000899243-19-027116","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-027116","line_url":"/filing/0000899243-19-027116#line-2","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Galera Therapeutics, Inc.","issuer_ticker":"GRTX","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Venture Partners IX, L.P.; POWELL MICHAEL; Mehra Anand; HEALY JAMES; Sofinnova Management IX, L.L.C.","owner_display_name":"Sofinnova Venture Partners IX, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":750000.0,"shares_display":"750,000","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":9000000.0,"total_display":"9,000,000.00","total_whole":"9,000,000","shares_owned_after":3083712.0,"shares_owned_after_display":"3,083,712","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-12","filed_date":"2019-11-12","scope":"insider"},{"id":7974444,"accession":"0001144204-19-026681","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-19-026681","line_url":"/filing/0001144204-19-026681#line-5","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Management IX, L.L.C.; HEALY JAMES; Mehra Anand; Sofinnova Venture Partners IX, L.P.; POWELL MICHAEL","owner_display_name":"Sofinnova Management IX, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6000000.0,"total_display":"6,000,000.00","total_whole":"6,000,000","shares_owned_after":2521856.0,"shares_owned_after_display":"2,521,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":5966240,"accession":"0001209191-18-053539","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-053539","line_url":"/filing/0001209191-18-053539#line-3","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Mehra Anand; HEALY JAMES; Sofinnova Management IX, L.L.C.; POWELL MICHAEL; Sofinnova Venture Partners IX, L.P.","owner_display_name":"Mehra Anand","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":337724.0,"shares_display":"337,724","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":5065860.0,"total_display":"5,065,860.00","total_whole":"5,065,860","shares_owned_after":1180178.0,"shares_owned_after_display":"1,180,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-28","filed_date":"2018-10-02","scope":"insider"},{"id":6228747,"accession":"0001144204-18-031803","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-18-031803","line_url":"/filing/0001144204-18-031803#line-4","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Iterum Therapeutics plc","issuer_ticker":"ITRM","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Management IX, L.L.C.; Mehra Anand; Sofinnova Venture Partners IX, L.P.; POWELL MICHAEL","owner_display_name":"Sofinnova Management IX, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":6500000.0,"total_display":"6,500,000.00","total_whole":"6,500,000","shares_owned_after":1726514.0,"shares_owned_after_display":"1,726,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-05-30","scope":"insider"},{"id":8847515,"accession":"0001209191-15-043025","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-043025","line_url":"/filing/0001209191-15-043025#line-2","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"aTYR PHARMA INC","issuer_ticker":"LIFE","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"HEALY JAMES; POWELL MICHAEL; Sofinnova Venture Partners IX, L.P.; Mehra Anand; Sofinnova Management IX, L.L.C.","owner_display_name":"HEALY JAMES","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":320000.0,"shares_display":"320,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":4480000.0,"total_display":"4,480,000.00","total_whole":"4,480,000","shares_owned_after":1866126.0,"shares_owned_after_display":"1,866,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-12","filed_date":"2015-05-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001651431","name":"Checkmate Pharmaceuticals, Inc.","url":"/issuer/0001651431","role":"Ten percent owner","n_filings":1,"first_seen":"2020-08-12","last_seen":"2020-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001659323","name":"Iterum Therapeutics plc","url":"/issuer/0001659323","role":"Ten percent owner","n_filings":2,"first_seen":"2018-05-30","last_seen":"2020-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001661059","name":"NextCure, Inc.","url":"/issuer/0001661059","role":"Ten percent owner","n_filings":2,"first_seen":"2019-05-15","last_seen":"2019-11-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001563577","name":"Galera Therapeutics, Inc.","url":"/issuer/0001563577","role":"Ten percent owner","n_filings":1,"first_seen":"2019-11-12","last_seen":"2019-11-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001724344","name":"Entasis Therapeutics Holdings Inc.","url":"/issuer/0001724344","role":"Ten percent owner","n_filings":1,"first_seen":"2018-10-02","last_seen":"2018-10-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001339970","name":"aTYR PHARMA INC","url":"/issuer/0001339970","role":"Ten percent owner","n_filings":1,"first_seen":"2015-05-14","last_seen":"2015-05-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001612134","retrieved_at":"2026-08-23T14:55:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}